17.83
price down icon0.89%   -0.16
after-market Dopo l'orario di chiusura: 17.85 0.02 +0.11%
loading

Myriad Genetics Inc Borsa (MYGN) Ultime notizie

pulisher
Nov 04, 2024

UnitedHealthcare limits coverage for Myriad's GeneSight test - Investing.com

Nov 04, 2024
pulisher
Nov 04, 2024

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Myriad Genetics, Inc. (MYGN) And Encourages Stockholders to Reach Out - AccessWire

Nov 04, 2024
pulisher
Nov 04, 2024

Myriad Genetics (NASDAQ:MYGN) Shares Down 4.6%Here's Why - MarketBeat

Nov 04, 2024
pulisher
Nov 04, 2024

Myriad Genetics Inc (MYGN) Trading Down 3.81% on Nov 4 - GuruFocus.com

Nov 04, 2024
pulisher
Nov 04, 2024

Myriad Genetics in Active Talks with UnitedHealthcare to Keep Coverage of GeneSight - MarketWatch

Nov 04, 2024
pulisher
Nov 04, 2024

UnitedHealthcare limits coverage for Myriad's GeneSight test By Investing.com - Investing.com UK

Nov 04, 2024
pulisher
Nov 04, 2024

Myriad Genetics Comments on UnitedHealthcare’s Updated Medical Policy for Pharmacogenetic Testing - GlobeNewswire

Nov 04, 2024
pulisher
Nov 03, 2024

Trading (MYGN) With Integrated Risk Controls - Stock Traders Daily

Nov 03, 2024
pulisher
Nov 02, 2024

Myriad weakness due to UnitedHealth coverage update, says Stephens - Yahoo Finance

Nov 02, 2024
pulisher
Nov 02, 2024

Why Investors Shouldn't Be Surprised By Myriad Genetics, Inc.'s (NASDAQ:MYGN) 33% Share Price Plunge - Simply Wall St

Nov 02, 2024
pulisher
Nov 02, 2024

Is Myriad Genetics (NASDAQ:MYGN) A Risky Investment? - Simply Wall St

Nov 02, 2024
pulisher
Nov 02, 2024

Myriad Genetics, Inc. (NASDAQ:MYGN) Given Consensus Rating of "Hold" by Analysts - MarketBeat

Nov 02, 2024
pulisher
Nov 01, 2024

Myriad Genetics Shares Slip 21% on UnitedHealthcare Coverage Changes - MarketWatch

Nov 01, 2024
pulisher
Nov 01, 2024

Myriad Genetics plummets 20% as UnitedHealth changes GeneSight coverage - Seeking Alpha

Nov 01, 2024
pulisher
Nov 01, 2024

Myriad Genetics (NASDAQ:MYGN) Shares Gap DownWhat's Next? - MarketBeat

Nov 01, 2024
pulisher
Oct 31, 2024

Myriad Genetics (MYGN) to Release Quarterly Earnings on Thursday - MarketBeat

Oct 31, 2024
pulisher
Oct 30, 2024

Myriad Genetics to Release Third Quarter 2024 Financial Results on November 7, 2024 - GlobeNewswire

Oct 30, 2024
pulisher
Oct 30, 2024

Assenagon Asset Management S.A. Reduces Stock Position in Myriad Genetics, Inc. (NASDAQ:MYGN) - MarketBeat

Oct 30, 2024
pulisher
Oct 28, 2024

Myriad Genetics (MYGN) Earnings Expected to Grow: Should You Buy? - Yahoo Finance

Oct 28, 2024
pulisher
Oct 27, 2024

Myriad Genetics 2008A Retrospective - RTTNews

Oct 27, 2024
pulisher
Oct 27, 2024

Myriad Genetics Q4 Profit Declines, Yet Tops EstimateUpdate - RTTNews

Oct 27, 2024
pulisher
Oct 27, 2024

Myriad Genetics Swings to Q3 Profit - RTTNews

Oct 27, 2024
pulisher
Oct 27, 2024

Myriad Genetics Q1 Profit More Than Doubles, Yet Misses Estimate - RTTNews

Oct 27, 2024
pulisher
Oct 27, 2024

Making Peace With Rivals For A Slice Of BRCA... - RTTNews

Oct 27, 2024
pulisher
Oct 25, 2024

Relationship Tests Market Size 2024: Industry Overview, - openPR

Oct 25, 2024
pulisher
Oct 23, 2024

What We Don’t Know Can Hurt: New Survey Reveals Knowledge Gaps About Breast Density and Cancer Risk - North American Precis Syndicate, Inc.

Oct 23, 2024
pulisher
Oct 23, 2024

(MYGN) Pivots Trading Plans and Risk Controls - Stock Traders Daily

Oct 23, 2024
pulisher
Oct 21, 2024

Myriad: Q2 Earnings Snapshot - Barchart

Oct 21, 2024
pulisher
Oct 18, 2024

Myriad Genetics Shares Fall Despite Partnership With jscreen - Yahoo Finance

Oct 18, 2024
pulisher
Oct 18, 2024

OmniStar Financial Group Inc. Makes New $863,000 Investment in Myriad Genetics, Inc. (NASDAQ:MYGN) - MarketBeat

Oct 18, 2024
pulisher
Oct 17, 2024

Direct-To-Consumer Genetic Testing Market to Grow by USD 1.22 Billion from 2024-2028, Driven by Early Disease Diagnosis and AI-Driven Market TransformationTechnavio - The Malaysian Reserve

Oct 17, 2024
pulisher
Oct 17, 2024

Myriad Genetics partners with jscreen for genetic testing By Investing.com - Investing.com Australia

Oct 17, 2024
pulisher
Oct 16, 2024

Myriad Genetics partners with jscreen for genetic testing - Investing.com

Oct 16, 2024
pulisher
Oct 16, 2024

Myriad Genetics and jscreen™ Announce Strategic Partnership to Advance Health Equity and Genetic Testing Access - GlobeNewswire

Oct 16, 2024
pulisher
Oct 16, 2024

21,968 Shares in Myriad Genetics, Inc. (NASDAQ:MYGN) Purchased by Sanctuary Advisors LLC - MarketBeat

Oct 16, 2024
pulisher
Oct 15, 2024

Myriad's MyRisk test integrated into Flatiron's OncoEMR - Investing.com

Oct 15, 2024
pulisher
Oct 15, 2024

Myriad's MyRisk test integrated into Flatiron's OncoEMR By Investing.com - Investing.com Canada

Oct 15, 2024
pulisher
Oct 15, 2024

Myriad Genetics and Flatiron Health Partner to Make Genetic - GlobeNewswire

Oct 15, 2024
pulisher
Oct 15, 2024

Myriad Genetics and Flatiron Health Partner to Make Genetic Testing More Accessible with Electronic Medical Record Integration - StockTitan

Oct 15, 2024
pulisher
Oct 14, 2024

Cancer Genomic Testing Market – 37% of Growth to Originate from APAC -Myriad Genetics, Centogene AG, Color Genomics, Que – IndiaPolitics.com - IndiaPolitics.com

Oct 14, 2024
pulisher
Oct 14, 2024

Scotiabank reiterates positive outlook on Myriad Genetics shares By Investing.com - Investing.com UK

Oct 14, 2024
pulisher
Oct 14, 2024

SG Americas Securities LLC Takes $649,000 Position in Myriad Genetics, Inc. (NASDAQ:MYGN) - MarketBeat

Oct 14, 2024
pulisher
Oct 14, 2024

Global Consumer Genomics Market Huge Growth in Future Scope - openPR

Oct 14, 2024
pulisher
Oct 14, 2024

Myriad Genetics (NASDAQ:MYGN) shareholders are still up 61% over 1 year despite pulling back 7.9% in the past week - Yahoo Finance

Oct 14, 2024
pulisher
Oct 14, 2024

Brokers Offer Predictions for Myriad Genetics, Inc.'s Q1 2025 Earnings (NASDAQ:MYGN) - MarketBeat

Oct 14, 2024
pulisher
Oct 12, 2024

Learn to Evaluate (MYGN) using the Charts - Stock Traders Daily

Oct 12, 2024
pulisher
Oct 11, 2024

Myriad Genetics, Inc. (NASDAQ:MYGN) CEO Sells 15,000 Shares - MarketBeat

Oct 11, 2024
pulisher
Oct 11, 2024

Insider Sale: President and CEO Paul Diaz Sells 15,000 Shares of Myriad Genetics Inc (MYGN) - GuruFocus.com

Oct 11, 2024
pulisher
Oct 11, 2024

Myriad Genetics CEO Paul J. Diaz sells $343,950 in stock By Investing.com - Investing.com South Africa

Oct 11, 2024
pulisher
Oct 11, 2024

Myriad Genetics CEO Paul J. Diaz sells $343,950 in stock - Investing.com

Oct 11, 2024
pulisher
Oct 11, 2024

Insiders At Myriad Genetics Sold US$6.5m In Stock, Alluding To Potential Weakness - Simply Wall St

Oct 11, 2024
pulisher
Oct 11, 2024

Pharmacogenomics Industry Report 2024: Analysis by Technology, Application, End-user, Region, and Company with Growth Forecasts to 2032 - GlobeNewswire Inc.

Oct 11, 2024
pulisher
Oct 11, 2024

Stephens increases Myriad Genetics stock target on growth outlook By Investing.com - Investing.com Canada

Oct 11, 2024
pulisher
Oct 11, 2024

Breast Cancer Liquid Biopsy Market is expected to Double Its Size - openPR

Oct 11, 2024
pulisher
Oct 11, 2024

MYGN Taps Ultima Genomics' UG 100 Platform for Advanced Clinical Tests - Yahoo Finance

Oct 11, 2024
pulisher
Oct 11, 2024

Leerink maintains Outperform rating on Myriad Genetics stock with updated revenue estimates - Investing.com Canada

Oct 11, 2024
pulisher
Oct 11, 2024

JPMorgan attends Myriad Genetics investor day, holds stock rating at Underweight By Investing.com - Investing.com Canada

Oct 11, 2024
pulisher
Oct 09, 2024

Myriad Genetics (NASDAQ:MYGN) Shares Gap UpStill a Buy? - MarketBeat

Oct 09, 2024
pulisher
Oct 09, 2024

Myriad Genetics advances breast cancer MRD testing research By Investing.com - Investing.com Australia

Oct 09, 2024
$218.80
price down icon 0.73%
diagnostics_research LH
$227.17
price up icon 0.03%
diagnostics_research WAT
$387.34
price up icon 0.03%
$153.49
price up icon 2.49%
diagnostics_research MTD
$1,364.02
price up icon 1.63%
$414.52
price down icon 0.66%
Capitalizzazione:     |  Volume (24 ore):